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Abstract
Aims—To determine the association of metabolic syndrome (MetS) and its components with
diabetes risk in participants with impaired glucose tolerance (IGT), and whether intervention-
related changes in MetS lead to differences in diabetes incidence.
Methods—We used the NCEP/ATP III revised MetS definition at baseline and intervention-
related changes of its components to predict incident diabetes using Cox models in 3234 Diabetes
Prevention Program (DPP) participants with IGT over an average follow-up of 3.2 years.
Results—In an intention-to-treat analysis, the demographic-adjusted hazard ratios (95%CI) for
diabetes in those with MetS (versus no MetS) at baseline were 1.7(1.3-2.3), 1.7(1.2-2.3), and
2.0(1.3-3.0) for placebo, metformin, and lifestyle groups, respectively. Higher levels of fasting
plasma glucose and triglycerides at baseline were independently associated with increased risk of
diabetes. Greater waist circumference (WC) was associated with higher risk in placebo and
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lifestyle groups, but not in the metformin group. In a multivariate model, favorable changes in WC
(placebo and lifestyle) and HDLc (placebo and metformin) contributed to reduced diabetes risk.
Conclusions—MetS and some of its components are associated with increased diabetes
incidence in persons with IGT in a manner that differed according to DPP intervention. After
hyperglycemia, the most predictive factors for diabetes were baseline hypertriglyceridemia and
both baseline and lifestyle-associated changes in waist circumference. Targeting these cardio-
metabolic risk factors may help to assess the benefits of interventions that reduce diabetes
incidence.
Keywords
diabetes prevention; cardio-metabolic risk; lifestyle; metformin
INTRODUCTION
Metabolic syndrome (MetS) consists of clustering risk factors that may be targeted for risk
reduction of cardiovascular disease (CVD) and diabetes. MetS predicts the incidence of type
2 diabetes in population-based studies of normoglycemic individuals [1-2]. Whether MetS
and its components predict diabetes in higher-risk individuals with IGT is less well studied.
IGT is associated with atherosclerosis and increased arterial stiffness, which may lead to
elevated pulse pressure (PP), further increasing the risk of diabetes and CVD [3-4]. In
addition, the combination of elevated waist circumference and triglyceride– so called
hypertriglyceridemic waist, has been demonstrated to be a superior predictor of insulin
resistance and intra-abdominal fat [5], but its utility as a predictor of incident diabetes in
individuals with IGT has not been assessed. It is not known whether intervention-associated
changes in these cardio-metabolic risk factors will also reduce diabetes incidence.
The DPP, a multicenter, randomized controlled trial, demonstrated that the risk for
developing diabetes was reduced 58% by intensive lifestyle (ILS) and 31% by metformin
(MET) interventions in people with IGT, compared with placebo (PLA) [6]. The DPP data
provides a unique opportunity to evaluate the associations of MetS and its components at
baseline and their changes after intervention with the development of diabetes.
METHODS
Study participants
The eligibility criteria, design, and methods of the DPP have been reported elsewhere [6, 7].
Selection criteria included: age ≥25 years, BMI ≥24 kg/m2 (≥22 kg/m2 in Asian Americans),
fasting plasma glucose (FPG) levels between 95 and 125 mg/dl, and IGT (2-hour post-load
glucose of 140–199 mg/dl). Persons were excluded if they were taking medications known
to alter glucose tolerance or if they had illnesses that could seriously reduce their life
expectancy or their ability to participate in the trial. The current report includes 3234
participants, who were randomized into 3 treatment arms, namely ILS, MET, and PLA.
Written informed consent was obtained from all participants before screening, consistent
with the Declaration of Helsinki and the guidelines of each center’s institutional review
board.
Clinical and metabolic variables—Standardized interviewer-administered
questionnaires were used to obtain demographic and clinical data. Blood pressure (BP),
weight, and waistcircumference (WC) were measured biannually using standard techniques.
All analytical measurements for glucose, insulin, and lipids were performed at the Central
Biochemistry Laboratory (Northwest Lipid Research Laboratories, University of
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Washington, Seattle, WA) as reported previously. Insulin secretion was estimated with the
corrected insulin response (CIR) = (100 × 30-min insulin)/(30-min glucose × [30-min
glucose – 70 mg/dl]) [8]. Insulin resistance was estimated using the reciprocal of fasting
insulin.
Outcomes—Development of diabetes was determined by an annual oral glucose tolerance
test and semiannual FPG tests, and required confirmation by a second test using the
diagnostic criteria of the American Diabetes Association and the World Health Organization
[9, 10].
Data Analysis
We classified participants into those with MetS, using the revised National Cholesterol
Education Program/Adult Treatment Panel III (NCEP/ATP III) definition [11], if they had 3
or more of the following criteria: (a) WC≥40 inches (102 cm) in men or ≥ 35 inches (88cm)
in women; (b) triglyceride ≥1.7 mmol/L (150 mg/dl) or use of lipid lowering medications;
(c) HDL-C <1.03 mmol/L (40 mg/day)in men or <1.29 mmol/L(50 mg/dl)in women or use
of lipid lowering medications; (d) systolic BP (SBP)≥130 mm Hg, diastolic BP (DBP) ≥85
mm Hg, or use of antihypertensivetherapy; and (e) FPG≥5.6 mmol/L (100 mg/dL). For
comparison, the International Diabetes Federation (IDF) definition [12] was also used to
identify those with MetS if they had a WC ≥94 cm in men or ≥80 cm in women plus any
two of the following: (a) triglycerides ≥1.7 mmol/L or specific treatment for this lipid
abnormality; (b) HDL-C<1.03 mmol/L in men or<1.29 mmol/L in women or specific
treatment for this lipid abnormality; (c) SBP ≥130 mmHg or DBP ≥85 mmHg or treatment
of previously diagnosed hypertension; and (d)FPG ≥5.6 mmol/L. PP was calculated from the
difference between SBP and DBP measurements at baseline and in semi-annual visits.
Hypertriglyceridemic waist was defined using the same MetS cutpoints for TG and WC.
Participants were followed for an average of 3.2 years.Mean differences between groups
were tested using the t test, within groups using the paired t test, and differences in
proportions using the contingency chi-squared test. The normal errors longitudinal
regression model assessed differences between groups in the mean change from baseline up
to the time of diabetes onset or the last visit, adjusting for baseline values.
The Cox proportional hazards model [13] was used to assess the association between the
covariatesand diabetes onset, adjusted for baseline demographic variables (age at
randomization, sex, and race/ethnicity). Multivariate models were used to examine
individual and adjusted contributions of the MetS components. The Wald test provided p-
values and R2 values for individual covariates; and the likelihood ratio test tested those for
the combined model. Madalla’s partial R2 described the proportion of variation in risk of
diabetes explained by a covariate, expressed as a percentage [14]. To facilitate comparisons
across variables, hazard ratios are reported for convenient increments approximating one
standard deviation (SD) of measure. Models were run separately for each treatment group,
and a test of heterogeneity was used to see if the association differed across treatment
groups. Besides the use of MetS definition based on the dichotomization of thresholds, we
examined the effect of each MetS component as a quantitative trait to obtain greater
granularity on its specific contribution. In assessing the relationship between intervention-
related changes in components and the risk for diabetes, the Cox models accounted for
differences in age at randomization, sex, race/ethnicity, baseline FPG, and baseline level.
Metabolic variables in the time-dependent proportional hazards analyses were entered as the
average change from baseline up to, but not including, each visit when diabetes was
diagnosed; and hazard ratios are expressed as a favorable change approximating one SD.
The SAS system was used for all analyses (Cary, NC). Interactions in Cox models were used
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to assess whether the association between baseline MetS and incident diabetes differed by
sex, age, or race/ethnicity.
RESULTS
We previously reported that baseline MetS prevalence using the original NCEP/ATP III
criteria was 53% [15]. Using the revised NCEP/ATP III definition, the observed prevalence
was 69%, which was similar to a 66% prevalence based on the IDF definition. Participants
who met the NCEP/ATP III MetS definition were heavier, had greater PP, more insulin
resistance, and lower insulin secretion than those without MetS (Table 1); and there was a
greater proportion of Caucasians and fewer African Americans in this group. Those with
MetS at baseline had higher risk of developing diabetes compared to those without MetS
(HR [95% CI]: ILS: 1.7[1.3-2.3]; MET: 1.7[1.2-2.3]; PLA: 2.0[1.3-3.0]) (Fig 1A). Similar
results were observed using the IDF MetS definition (HR [95% CI]: ILS; 1.7[1.2-2.5], MET;
1.4[1.1-1.9], and PLA; 1.7[1.3-2.2]). The impact of MetS at baseline did not differ by
treatment group (p=0.85), age, sex, or race/ethnicity.
As expected, participants with baseline fasting hyperglycemia (≥100 mg/dl) had 2-3 times
higher risk of developing diabetes compared to those with normal FPG at baseline in
univariate analyses. In addition, abdominal obesity at baseline was associated with higher
diabetes risk in the ILS and PLA groups (PLA: 1.6 [1.1-2.2], p=0.006; ILS: 1.8 [1.1-2.8],
p=0.02), but not in the MET group. Elevated triglycerideswere associated with incident
diabetes in the MET group only (1.4 [1.1-1.8], p=0.02); and low HDL-C was associated with
increased diabetes riskonly in the PLA group (1.4 [1.1-1.8] p=0.003). The baseline
prevalence of hypertriglyceridemic waist was 36.5% and was associated with approximately
half the excess risk for diabetes observed with the full MetS in the PLA (1.4 [1.1-1.8],
p=0.006) and ILS (1.6; 1.1-2.2 p=0.01) groups, but was not significantly associated with
diabetes risk in MET participants (1.28 [0.98-1.7] p=0.07). In multivariate analysis with
demographic factors plus all MetS components in the model (Figure 1B), only high FPG (in
all groups) and abdominal obesity (in ILS and PLA) remained significantly associated with
an increased risk of diabetes.For each 12 mmHg increment in baseline PP diabetes incidence
was increased by17%(p=0.013) and 23% (p=0.025) in PLA and ILS participants,
respectively, but not in those on MET (8%, p=0.3).
In order to have more power to detect the association between MetS components and
incident diabetes, absolute levels were used(Figs 2A and 2B). For every 8 mg/dl (0.44
mmol/l) higher FPG at baseline,diabetes risk nearly doubled in PLA and ILS groups. For
each 96 mg/dl (1.1 mmol/l) baseline triglyceride increment, diabetes incidence was
increased by 13% (p=0.01), 24% (p<0.001) and 20% (p=0.013) for the PLA, MET and ILS
groups, respectively; and for every 15 cm greater WC, diabetes incidence was 36%
(p<0.001) and 52% (p<0.001) greater in the PLA and ILS groups, respectively, with no
effect in the MET group. The association between WC and triglyceride on incident diabetes
remained significant after adjusting for FPG (Fig 2b) with the exception of WC in the MET
group. In additional models, there was no significant triglyceride by WC interaction in any
of the treatment groups, and the effects of triglyceride and WC on diabetes development
remained significant after accounting for baseline values of known diabetes predictors,
namely weight, insulin secretion, and insulin sensitivity (data not shown).Triglyceride and
WC increments per SD contributed to more of the variance in incident diabetes (for WC in
the PLA and ILS respectively, R2=1.2% and 2.8%, and for triglyceride in the PLA, ILS and
MET, R2=0.7%, 0.6% and 1.2%) than that associated with the category (for PLA and ILS,
R2=0.7% and 0.6%).
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Table 2 shows the changes from baseline for each MetS component during 3.2 years of
intervention according to the DPP intervention group and their effect on incident diabetes.
Favorable changes in eachcomponent were significantly associated with a reduction in
diabetes for all treatment groups, except for BP and TG in the MET group (Figure 2C). In a
multivariate model of baseline and changes in components (Fig 2D), baseline FPG remained
the primary determinant of subsequent diabetes. A reduction in WC of 6 cm decreased
diabetes risk by 45% in the ILS and 23% in the PLA buthad no effect in the MET groups. In
addition, an increase of 6 mg/dl (0.16 mmol/L) in HDL-C was independently associated
with a 20% reduction in diabetes risk in the MET and PLA groups, while changes in
triglyceride values had no effect on incident diabetes in any group. Unlike baseline WC and
triglyceride, the association of changes in WC and HDL-C with incident diabetes
disappeared after accounting for changes in weight, insulin secretion, and insulin sensitivity
(data not shown).In proportional hazards model adjusted for demographic and baseline PP, a
decrease of 9 mmHg of PP was associated with a reduction in diabetes risk in the MET (by
18%, p=0.02) and ILS (by 26%, p=0.011) groups but not in those in the PLA group (12%,
p=0.07). The significant association remained only in the MET group in the model after
further adjustment for changes in HDL, TG, and WC.
DISCUSSION
We found that the baseline presence of MetS, using either the revised NCEP/ATP III or IDF
definitions (66-69% of the population) was associated with anincreased risk of diabetes by
70-100% in DPP participants with IGT across age, sex, race, and intervention groups.
Among cardio-metabolic risk factors studied, increased WC and PP in the ILS and PLA, and
elevated TG in all three groups, were each associated with a higher risk of diabetes, while a
change in WC but not TG predicted diabetes development in the ILS and PLA. Previous
reports have demonstrated that MetS increases diabetes risk [1-2] although none assessed
diabetes using repeated glucose measures (OGTT or fasting samples) as was done here. One
study of Mexican Americans and non-Hispanic whites with IGT found that MetS was
associated with incident diabetes in adults with IGT [2]. Our report extends these
observations to a larger, multiethnic population and explores the effect of intervention-
related changes in MetS components and PP on risk of progression from IGT to diabetes.
As expected, baseline FPG was the strongest component linking MetS with incident
diabetes. TG levels had additional predictive properties, as has previously been reported
[16], in all intervention groups. Hypertriglyceridemia, in this setting, is thought to reflect
mainly the effects of insulin resistance on adipose tissue, muscle, and liver, and is likely not
directly involved in the pathophysiologic pathway to diabetes development [17], which may
explain why changes in TG were less effective predictors of diabetes risk. However, after
adjustment for weight and surrogates of insulin resistance and secretion, baseline TG
remained a significant predictor, suggesting an association with diabetes development
through other pathways.
The utility of WC as a predictor of incident diabetes has been amply demonstrated [18-20].
We found that both baseline and changes in WC were independently associated with
incident diabetes in the ILS and PLA groups, suggesting that WC may be directly linked to
diabetes development. Since the predictive effect of baseline WC remained significant after
adjusting for glycemia, insulin resistance, and secretion measures, other pathways, such as
inflammation, may also be involved [21]. By contrast, neither baseline WC, nor change in
WC was associated with incident diabetes in the MET group. It is possible that metformin
blunts the effect of obesity on diabetes risk, because its ameliorative effect on diabetes
development occurs mainly in those in the upper tertile of WC at baseline. Nevertheless,
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changes in weight associated with MET treatment contributed to its ability to reduce
diabetes development [22].
TG and WC were the individual cardio-metabolic risk factors that remained associated with
incident diabetes after adjustment for FPG; therefore participants with both abnormalities
were especially at risk. Hypertriglyceridemic waist was shown to be a simple tool to identify
participants at increased cardiometabolic risk and might better quantify visceral obesity and
its health hazards than WC alone [5]. Hypertriglyceridemic waist was present in 35% of
DPP participants and was a useful predictor of diabetes in the ILS and PLA but not the MET
group, whether the glucose level was elevated or not. However, hypertriglyceridemic waist
does not account for the deleterious effects of incremental elevations of either TG or WC
above categorical cut-points; therefore its predictive utility is limited. These findings serve
to emphasize the advantages of evaluating specific MetS components individually and as
continuous variables rather than as categories.
Although HDL-C has been demonstrated to predict diabetes [16, 23], it was only marginally
associated with incident diabetes in the PLA, while an increase in HDL-C was associated
with a reduction of diabetes risk only in the MET and PLA groups in the multivariate model.
The basis for the inverse association between HDL-C and diabetes development is poorly
understood. Low HDL-C in insulin-resistant states is thought to be due to remodeling of
HDL as a consequence of hypertriglyceridemia; and HDL-C has been shown to correlate
strongly with measures of insulin resistance [21]. Why increases in HDL-C in the MET
group are associated with protection against diabetes development, while those
accompanying ILS are not, is also unclear. It is possible that the effects of saturated fat
restriction, which tends to lower HDL-C, may have confounded the relationship between
HDL-C and diabetes development in the ILS, whereas MET has been shown to increase
HDL-C slightly; this may be linked to its effect on diabetes prevention.
It is somewhat surprising that baseline BP was not associated with diabetes development in
DPP, as has been previously reported in a population study [24]. However, baseline PP was
associated with increased risk for diabetes. This is consistent with a recent report in high-
risk Japanese hypertensive patients showing that PP is an independent predictor of new-
onset diabetes and suggesting that increased arterial stiffness and microvascular dysfunction
are associated with the development of diabetes [4]. Microvascular dysfunction may
contribute to impaired insulin-mediated changes in muscle perfusion and glucose
metabolism, providing a framework to understanding the association among obesity,
hypertension, and impaired insulin-mediated glucose disposal [25, 26]. Changes in PP were
predictive of diabetes only in the MET group in the multivariate model. It is conceivable
that the effects of lifestyle on diabetes prevention do not parallel its effects on BP and PP,
while in the metformin group these effects are more closely aligned [27]. Alternatively, the
changes in BP as participants progressed from IGT to diabetes may be too small to be
significant [28]. Others have shown an association of PP with MetS and its components,
particularly in non-diabetic individuals [29] but more research would be needed to better
understand these associations in the context of patients at high-risk for diabetes and CVD.
In conclusion, the DPP confirmed that the presence of MetS at baseline is associated with an
increased risk of worsening to diabetes in participantswith IGT, most of whom were also
overweight or obese. After adjustment for fasting glucose levels at baseline, an increased
diabetes risk is associated with elevated WC, PP, and TG. Our study evaluated baseline and
follow-up measurement of these cardio-metabolic risk factors. Previous studies relied solely
on baseline MetS data to assess diabetes risk while we were able to assess the impact that
changes in MetS components resulting from DPP interventions had on the incidence of
diabetes. Favorable lifestyle-associated changes in waist and HDL-C risk factors are
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associated with diabetes risk reduction, whereas in those treated with MET, changes in PP
are predictive of diabetes. Regardless of the various diagnostic criteria for the MetS and the
concerns about its clinical value [30], our findings underscore the value of identifying
cardio-metabolic abnormalities among individuals with high risk for diabetes as well as
targeting them for lifestyle and other interventions. Recent data analysis suggest that both
lifestyle and pharmacological interventions can reverse MetS, but the evidence is limited on
whether these benefits are sustained and translate into long-term prevention of CVD and
diabetes [31].
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Figure 1. Demographically adjusted hazard ratio (95%CI) for developing diabetes associated
with baseline metabolic syndrome and components
All hazard ratios are adjusted for age randomized, sex, and race/ethnicity. Components with
an asterisk (*) denote significant heterogeneity among the treatment groups. Metabolic
syndrome components are defined as: High FPG, fasting plasma glucose ≥ 100 mg/dl;
abdominal obesity, waist ≥ 102 cm in men and ≥ 88 cm in women; High TG, triglycerides
≥ 150 mg/dl or use of TG lowering medications; High BP, systolic/diastolic blood pressure
≥ 130/85 mmHg or use of antihypertensive medications; Low HDL-c, high density
lipoprotein cholesterol<40mg/dl in men and <50 in women or use of lipid lowering
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medications.High TG and abdominal obesity is defined as TG ≥ 150 mg/dl and waist ≥ 102
cm in men (waist≥ 88 cm in women).
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Figure 2. Hazard ratio (95% CI) for developing diabetes associated with cardio-metabolic risk
factors as continuous variables
All hazard ratios are adjusted for age randomized, sex, and race/ethnicity and computed in
increments to approximate 1 SD of the baseline component and of the changes from
baseline. Components with an asterisk (*) denote significant heterogeneity among the
treatment groups. Changes in components are computed as the average change from baseline
up to, but not including, each visit when diabetes was diagnosed. To facilitate comparison
across variables, hazard ratios
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Table 1
Baseline characteristics by metabolic syndrome status*
Overall
(n=3234)
Without MetS
(n=1006)
With MetS
(n=2228)
p-value
Age (years) 50.6 ± 10.7 50.9 ± 11.2 50.5 ± 10.4 0.360
Female 2191 (67.7%) 669 (66.5%) 1522 (68.3%) 0.308
Race 0.001
 Caucasian (n [%]) 1768 (54.7%) 498 (49.5%) 1270 (57.0%)
 African American (n [%]) 645 (19.9%) 228 (22.7%) 417 (18.7%)
 Hispanic (n [%]) 508 (15.7%) 165 (16.4%) 343 (15.4%)
 American Indian (n [%]) 171 (5.3%) 65 (6.5%) 106 (4.8%)
 Asian (n [%]) 142 (4.4%) 50 (5.0%) 92 (4.1%)
Weight (kg) 94.2 ± 20.3 86.2 ± 18.2 97.8 ± 20.1 <0.001
Waist circumference (cm) 105.1 ± 14.5 98.2 ± 13.5 108.2 ± 13.9 <0.001
Systolic BP (mm Hg) 123.7 ± 14.7 118.1 ± 12.7 126.3 ± 14.8 <0.001
Diastolic BP (mm Hg) 78.3 ± 9.3 75.0 ± 7.9 79.8 ± 9.5 <0.001
Pulse pressure (mm Hg) 45.4 ± 11.8 43.1 ± 10.3 46.5 ± 12.2 <0.001
Triglyceride (mmol/l) 1.6 (1.1, 2.3) 1.2 (0.9,1.5) 1.9 (1.3, 2.5) <0.001
HDL-C (mmol/l) 1.18 ± 0.31 1.38 ± 0.31 1.09 ± 0.26 <0.001
Fasting glucose (mmol/l) 5.9 ± 0.5 5.8 ± 0.5 6.0 ± 0.4 <0.001
1/fasting insulin 0.04 (0.03, 0.06) 0.05 (0.04, 0.08) 0.04 (0.03,0.06) <0.001
CIR 0.54 (0.35, 0.80) 0.50 (0.31, 0.74) 0.56 (0.37, 0.82) <0.001
Data are expressed as n (%), mean ± SD, percentage, or median (IQR), as appropriate; MetS, metabolic syndrome; BP, blood pressure; HDL-C,
high density lipoprotein cholesterol; CIR, corrected insulin response
*
Metabolic syndrome status is defined using the revised NCEP/ATP III definition.
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Table 2
Mean changes (95% CI) in cardio-metabolic risk factors over 3.2 years of follow-up by treatment group
MetS Component Placebo Metformin Intensive Lifestyle
Fasting glucose (mmol/l) 0.21 (0.17, 0.24) −0.03 (−0.06,
0.0005)*
−0.053 (−0.089,
−0.017)*
Waist circumference
(cm)
−0.22 (−0.53,
0.094) −1.69 (−2.06, −1.32)
*
−5.18 (−5.59, −4.77)*†
Systolic BP (mmHg) −0.68 (−1.21,
−0.15)
−0.84 (−1.39, −0.29)
−3.37 (−3.94, −2.80) *†
Diastolic BP (mmHg) −1.04 (−1.39,
−0.69)
−1.21 (−1.56, −0.86)
−3.40 (−3.77, −3.03) *†
Pulse pressure (mmHg) 0.41 (−0.03, 0.84) 0.44 (−0.01, 0.90) 0.14 (−0.30, 0.58)
HDL-c (mmol/l) −0.01 (−0.02, 0) 0.01 (0.003, 0.02)* 0.03 (0.02, 0.04) *†
Triglyceride (mmol/l) −0.01 (−0.19, 0.18) −0.004 (−0.19, 0.18)
−0.18 (−0.37, 0.01) *†
*
P < 0.05 compared to placebo
†
P < 0.05 compared to Metformin; all means are adjusted for the baseline value. BP, blood pressure; HDL-c, high density lipoprotein cholesterol
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